Theravance Biopharma (NASDAQ: TBPH) reported Q1 EPS of ($0.34), $0.23 worse than the analyst estimate of ($0.11). Revenue for the quarter came in at $13.2 million versus the consensus estimate of $14.48 million.

Cash, cash equivalents and marketable securities totaled $147.5 million as of March 31, 2022.

For earnings history and earnings-related data on Theravance Biopharma (TBPH) click here.